CoImmune, Inc., a clinical stage immuno-oncology company, has announced the publication of a review of their clinical development program for CMN-001 in metastatic renal cell carcinoma (mRCC). The review evaluates CMN-001, which is a dendritic cell-based immunotherapy electroporated with autologous tumor RNA. This groundbreaking treatment aims to redefine cancer treatment using cellular immunotherapies. The review has been published in Human Vaccines & Immunotherapeutics, a peer-reviewed journal sponsored by the International Society for Vaccines.
Charles Nicolette, Ph.D., Chief Executive Officer of CoImmune, expressed that engineering dendritic cells to treat cancer has long been an aspiration for cell-based immunotherapies. CMN-001 is specifically designed to elicit an adaptive T-cell response against the antigens present in the patient's own tumor tissue. With over two decades of clinical experience with CMN-001, CoImmune is implementing lessons learned and advancing their development program to reflect the changing landscape of therapies available to treat mRCC.